STOCK TITAN

Vertex (VRTX) director Alan Garber granted RSUs and fully vested options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Vertex Pharmaceuticals director Alan M. Garber received equity awards as compensation. He was granted 472 shares of Common Stock in the form of restricted stock units that vest, subject to limited exceptions, on the first anniversary of the grant date. He was also granted stock options for 1,433 shares of Common Stock at an exercise price of $424.45 per share, which are fully vested and expire on April 30, 2036. Following the stock grant, he directly holds 7,344 shares of Vertex Common Stock in addition to these options.

Positive

  • None.

Negative

  • None.
Insider Garber Alan M
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 1,433 $0.00 --
Grant/Award Common Stock 472 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 1,433 shares (Direct, null); Common Stock — 7,344 shares (Direct, null)
Footnotes (1)
  1. Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Fully vested.
Restricted stock units granted 472 shares RSU award vesting on first anniversary of grant date
Options granted 1,433 options Stock Option (Right to Buy) granted to director
Option exercise price $424.45 per share Conversion or exercise price for 1,433 options
Option expiration date April 30, 2036 Expiration of newly granted stock options
Shares held after grant 7,344 shares Total Vertex Common Stock directly owned after RSU grant
Restricted stock unit financial
"Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with 1,433.0000 shares and exercise price 424.4500"
Fully vested financial
"Fully vested."
exercise price financial
"conversion_or_exercise_price: "424.4500" for the stock option grant"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Garber Alan M

(Last)(First)(Middle)
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE

(Street)
BOSTON MASSACHUSETTS 02210

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/01/2026A472(1)A$07,344D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$424.4505/01/2026A1,433 (2)04/30/2036Common Stock1,433$01,433D
Explanation of Responses:
1. Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.
2. Fully vested.
Remarks:
/s/ Christiana Stevenson, Attorney-in-Fact05/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Alan M. Garber receive in this Vertex (VRTX) Form 4 filing?

Alan M. Garber received equity compensation from Vertex, not an open-market trade. He was granted 472 restricted stock units and stock options for 1,433 shares of Common Stock, reflecting routine director compensation rather than a discretionary stock purchase or sale.

How many Vertex (VRTX) shares does Alan M. Garber hold after this grant?

After the grant, Alan M. Garber directly holds 7,344 shares of Vertex Common Stock. In addition, he holds stock options covering 1,433 underlying shares, giving him both current share ownership and the right to buy additional shares at a fixed exercise price.

What are the terms of Alan M. Garber’s new Vertex (VRTX) stock options?

Garber’s new stock options cover 1,433 shares of Vertex Common Stock at an exercise price of $424.45 per share. The filing states these options are fully vested and will expire on April 30, 2036, giving a long-dated right to purchase shares at that price.

When do Alan M. Garber’s Vertex (VRTX) restricted stock units vest?

The restricted stock unit award for 472 shares vests on the first anniversary of the grant date, subject to limited exceptions. This means Garber must remain eligible through that one-year period before the units convert into freely owned shares of Vertex Common Stock.

Does this Vertex (VRTX) Form 4 show Alan M. Garber buying or selling shares?

The Form 4 reports equity awards classified as acquisitions, not open-market buying or selling. Both the 472 restricted stock units and 1,433 stock options were granted as compensation, with no reported sales or purchases of Vertex shares in the public market in this filing.